Categories
Change Password!
Reset Password!
A study was performed to investigate the long-term efficacy and safety of orally administered ozanimod in individuals having moderate-to-severe ulcerative colitis with ≥four years of follow-up in phase II, randomized, placebo-controlled, TOUCHSTONE open-label extension.
In individuals suffering from
moderate-to-severe ulcerative colitis, 1 mg of ozanimod HCl daily has a favorable benefit-risk profile and long-term
benefit.
A study was performed to
investigate the long-term efficacy and safety of orally administered ozanimod
in individuals having moderate-to-severe ulcerative colitis with ≥four years of
follow-up in phase II, randomized, placebo-controlled, TOUCHSTONE open-label
extension.
Participants treated with ozanimod HCl 0.5 mg or 1 mg or placebo during the double-blind therapy period could enter an open-label extension trial (ozanimod HCl 1 mg daily). Evaluation of Partial Mayo score clinical response and remission were done through open-label extension week 200. Utilizing the observed cases and non-responder imputation (NRI), the findings were summarized descriptively.
At open-label extension week 56 and therapy end, endoscopy was required. The parameters
linked with endoscopy were suitably summarized at weeks 56 and 104 (observed
cases), and week 56 (NRI). Evaluation of C-reactive protein and fecal
calprotectin were done. Monitoring of adverse events was done throughout the
trial.
Of 197 subjects treated with double-blind therapy, 170 entered open-label extension trial. At year 1, the discontinuation rates were 28% and 15%-18% annually through year 4. At open-label extension week 200, the partial mayo measures demonstrated clinical response and remission rates of 93.3% and 82.7% respectively, utilizing observed cases and 41% and 37% with the more conservative NRI analysis.
At weeks 56 and 104, respectively, the histologic remission rates and endoscopic improvement rates (observed cases) is shown in the below table:
No novel safety signals were
recognized during the ≥4 years of follow-up. An elevated rate of continued
study participation was also noted.
In ulcerative colitis patients, the
consistent efficacy outcomes across clinical, endoscopic, histologic, and
biomarker measures indicate that long-term usage of ozanimod may alleviate
inflammation and lead to histologic and endoscopic disease remission,
manifested as sustained improvement in clinical symptoms of the disease.
The Journal of Crohn's and Colitis
https://academic.oup.com/ecco-jcc/advance-article/doi/10.1093/ecco-jcc/jjab012/6092404?login=true
Long-Term Efficacy And Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study
William J Sandborn et al.
Comments (0)